|
1
|
Enewold L, Zhu K, Ron E, Marrogi AJ,
Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer
incidence in the United States by demographic and tumor
characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev.
18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Clement SC, Peeters RP, Ronckers CM, Links
TP, van den Heuvel-Eibrink MM, van Nieveen Dijkum EJ, van Rijn RR,
van der Pal HJ, Neggers SJ, Kremer LC, et al: Intermediate and
long-term adverse effects of radioiodine therapy for differentiated
thyroid carcinoma - A systematic review. Cancer Treat Rev. Sept
10–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Thyroid Association (ATA)
Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid
Cancer. Cooper DS, Doherty GM, et al: Revised American Thyroid
Association management guidelines for patients with thyroid nodules
and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dequanter D and Lothaire P: Incidental
metastases of well-differentiated thyroid carcinoma in lymph nodes
of patient with squamous cell head and neck cancer: case report
with review of the literature. Rev Med Brux. 29:487–489. 2008.(In
French). PubMed/NCBI
|
|
5
|
Lee J and Soh EY: Differentiated thyroid
carcinoma presenting with distant metastasis at initial diagnosis
clinical outcomes and prognostic factors. Ann Surg. 251:114–119.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kammori M, Fukumori T, Sugishita Y, Hoshi
M, Shimizu K and Yamada T: Radioactive iodine (RAI) therapy for
distantly metastatic differentiated thyroid cancer (DTC) in
juvenile versus adult patients. Endocr J. Oct 1–2015.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shoback D: Clinical practice.
Hypoparathyroidism. N Engl J Med. 359:391–403. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Page C and Strunski V: Parathyroid risk in
total thyroidectomy for bilateral, benign, multinodular goitre:
report of 351 surgical cases. J Laryngol Otol. 121:237–241. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glazebrook GA: Effect of decicurie doses
of radioactive iodine 131 on parathyroid function. Am J Surg.
154:368–373. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guven A, Salman S, Boztepe H, Yarman S,
Tanakol R, Azizlerli H and Alagol F: Parathyroid changes after high
dose radioactive iodine in patients with thyroid cancer. Ann Nucl
Med. 23:437–441. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meng Z, Lou S, Tan J, Xu K, Jia Q and
Zheng W: Nuclear factor-kappa B inhibition can enhance apoptosis of
differentiated thyroid cancer cells induced by 131I.
PLoS One. 7:e335972012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chatterjee S: Permanent hypoparathyroidism
following radioiodine treatment for hyperthyroidism. 52:421–422.
2004.
|
|
13
|
Shamim SE, Nang LB, Shuaib IL and Muhamad
NA: Clinical determinants of fluorodeoxyglucose positron emission
tomography/computed tomography in differentiated thyroid cancer
patients with elevated thyroglobulin and negative
131iodine whole body scans after 131iodine
therapy. Malays J Med Sci. 21:38–46. 2014.PubMed/NCBI
|
|
14
|
Bravo PE, Goudarzi B, Rana U, Filho PT,
Castillo R, Rababy C, Ewertz M, Ziessman HA, Cooper DS, Ladenson
PW, et al: Clinical significance of discordant findings between
pre-therapy 123I and post-therapy 131I whole
body scan in patients with thyroid cancer. Int J Clin Exp Med.
6:320–333. 2013.PubMed/NCBI
|
|
15
|
Phan HT, Jager PL, Paans AM, Plukker JT,
Sturkenboom MG, Sluiter WJ, Wolffenbuttel BH, Dierckx RA and Links
TP: The diagnostic value of 124I-PET in patients with
differentiated thyroid cancer. Eur J Nucl Med Mol Imaging.
35:958–965. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Josefsson A and Forssell-Aronsson E:
Dosimetric analysis of 123I, 125I and 131I in thyroid follicle
models. EJNMMI Res. 4(23)2014.PubMed/NCBI
|
